169 related articles for article (PubMed ID: 35056058)
1. Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations.
Martín-Sabroso C; Alonso-González M; Fernández-Carballido A; Aparicio-Blanco J; Córdoba-Díaz D; Navarro-García F; Córdoba-Díaz M; Torres-Suárez AI
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056058
[TBL] [Abstract][Full Text] [Related]
2. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems, Part II: Long-Term Stability and Clinical Ocular Biopermanence.
Castro-Balado A; Cuartero-Martínez A; Pena-Verdeal H; Hermelo-Vidal G; Schmidt A; Montero B; Hernández-Blanco M; Zarra-Ferro I; González-Barcia M; Mondelo-García C; Giráldez MJ; Yebra-Pimentel E; Otero-Espinar FJ; Fernández-Ferreiro A
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004568
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmic Outcome in a Belgian Cohort of Cystinosis Patients Treated with a Compounded Preparation of Cysteamine Eye Drops: Retrospective Analysis.
Peeters F; Cassiman C; Van Keer K; Levtchenko E; Veys K; Casteels I
Ophthalmol Ther; 2019 Dec; 8(4):623-633. PubMed ID: 31560113
[TBL] [Abstract][Full Text] [Related]
4. Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.
Reda A; Van Schepdael A; Adams E; Paul P; Devolder D; Elmonem MA; Veys K; Casteels I; van den Heuvel L; Levtchenko E
JIMD Rep; 2018; 42():47-51. PubMed ID: 29214524
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches for improving stability of cysteamine formulations.
Dixon P; Powell K; Chauhan A
Int J Pharm; 2018 Oct; 549(1-2):466-475. PubMed ID: 30099213
[TBL] [Abstract][Full Text] [Related]
6. [Ocular treatment of cystinosis with eye drop containing cysteamine].
Csorba A; Maka E; Szabó A; Kelen K; Reusz G; Nagy ZZ
Orv Hetil; 2022 May; 163(21):846-852. PubMed ID: 35598215
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
[TBL] [Abstract][Full Text] [Related]
9. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.
Castro-Balado A; Bandín-Vilar E; Cuartero-Martínez A; García-Quintanilla L; Hermelo-Vidal G; García-Otero X; Rodríguez-Martínez L; Mateos J; Hernández-Blanco M; Aguiar P; Zarra-Ferro I; González-Barcia M; Mondelo-García C; Otero-Espinar FJ; Fernández-Ferreiro A
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297629
[TBL] [Abstract][Full Text] [Related]
10. The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series.
Biswas S; Sornalingam K
Ophthalmol Ther; 2019 Mar; 8(1):125-136. PubMed ID: 30519924
[TBL] [Abstract][Full Text] [Related]
11. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
[TBL] [Abstract][Full Text] [Related]
12. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
[TBL] [Abstract][Full Text] [Related]
13. A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability.
Jimenez J; Washington MA; Resnick JL; Nischal KK; Fedorchak MV
Drug Deliv Transl Res; 2021 Oct; 11(5):2224-2238. PubMed ID: 33543397
[TBL] [Abstract][Full Text] [Related]
14. A Comparative Pharmacokinetic Study for Cysteamine-Containing Eye Drops as an Orphan Topical Therapy in Cystinosis.
Csorba A; Katona G; Budai-Szűcs M; Balogh-Weiser D; Molnár P; Maka E; Kazsoki A; Vajna M; Zelkó R; Nagy ZZ; Balogh GT
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338900
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of topical cysteamine in nephropathic cystinosis.
Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
[TBL] [Abstract][Full Text] [Related]
16. [Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis].
Fernández-Ferreiro A; Luaces-Rodríguez A; Díaz-Tomé V; Gil-Martínez M; Rodríguez Ares MT; Touriño Peralba R; Blanco-Méndez J; González-Barcia M; Otero-Espinar FJ; Lamas MJ
Farm Hosp; 2017 Nov; 41(6):678-687. PubMed ID: 29112493
[TBL] [Abstract][Full Text] [Related]
17. [1H-NMR spectroscopic study of cysteamine eyedrops].
Gräf M; Kalinowski HO
Klin Monbl Augenheilkd; 1995 Apr; 206(4):262-5. PubMed ID: 7791287
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses.
Hsu KH; Fentzke RC; Chauhan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):531-40. PubMed ID: 23665502
[TBL] [Abstract][Full Text] [Related]
19. Ocular biodistribution of cysteamine delivered by a sustained release microsphere/thermoresponsive gel eyedrop.
Jimenez J; Resnick JL; Chaudhry AB; Gertsman I; Nischal KK; DiLeo MV
Int J Pharm; 2022 Aug; 624():121992. PubMed ID: 35809831
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]